TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $74.12

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $74.12, but opened at $76.08. TransMedics Group shares last traded at $77.49, with a volume of 52,152 shares.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Oppenheimer increased their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday, February 27th. Morgan Stanley increased their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. increased their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Finally, Piper Sandler assumed coverage on shares of TransMedics Group in a report on Thursday. They issued an “overweight” rating and a $95.00 price objective on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $102.00.

TransMedics Group Stock Performance

The company has a market cap of $2.45 billion, a P/E ratio of -96.26 and a beta of 2.01. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The stock’s 50-day moving average price is $83.45 and its 200 day moving average price is $70.01.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. The business had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. TransMedics Group’s quarterly revenue was up 158.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. As a group, research analysts expect that TransMedics Group, Inc. will post -0.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $80.41, for a total value of $804,100.00. Following the sale, the insider now owns 14,375 shares in the company, valued at approximately $1,155,893.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of the business’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total transaction of $209,909.70. Following the completion of the sale, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,295,043.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tamer I. Khayal sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now owns 14,375 shares of the company’s stock, valued at $1,155,893.75. The disclosure for this sale can be found here. Insiders have sold 92,949 shares of company stock worth $7,710,719 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of TMDX. Advisor Group Holdings Inc. grew its position in shares of TransMedics Group by 7.8% in the 1st quarter. Advisor Group Holdings Inc. now owns 13,173 shares of the company’s stock valued at $354,000 after purchasing an additional 948 shares during the period. JPMorgan Chase & Co. boosted its position in TransMedics Group by 25.5% during the 1st quarter. JPMorgan Chase & Co. now owns 12,767 shares of the company’s stock worth $343,000 after acquiring an additional 2,591 shares during the last quarter. HighTower Advisors LLC acquired a new position in TransMedics Group during the 1st quarter worth approximately $250,000. MetLife Investment Management LLC boosted its position in TransMedics Group by 68.2% during the 1st quarter. MetLife Investment Management LLC now owns 15,561 shares of the company’s stock worth $419,000 after acquiring an additional 6,307 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in TransMedics Group by 6.9% during the 1st quarter. Rhumbline Advisers now owns 25,205 shares of the company’s stock worth $679,000 after acquiring an additional 1,621 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.